Management of intravitreal injections;Manejo de las inyecciones intravítreas

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 84, Issue 8, 2009, Pages 377-388

  Gómez Ulla, Francisco ^a,b   Basauri, E ^c   Arias, L ^a,d   Martinez Sanz F ^a,e  

^a HOSPITAL DE CONXO   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL SON LLÀTZER   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Ant VEGF; Endophthalmitis; Intravitreal injection; Triamcinolone

Indexed keywords

ALGORITHM; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; METHODOLOGY; REVIEW; RISK FACTOR; VITREOUS BODY;

ALGORITHMS; HUMANS; INJECTIONS, INTRAOCULAR; RISK FACTORS; VITREOUS BODY;

EID: 77949763498     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Ohm J. Über die Behandlung der Netzhautablo?sung durch operative Entleerung der subretinalen Flössigkeit und Einspritzung von Luft in den Glaskörper. Albrecht von Graefes Arch Ophthalmol 1911; 79: 442-450.
2. Rycroft B. Penicillin and the control of deep intraocular infection. Br J Ophthalmol 1945; 29: 57-87.
3. Schneider J, Frankel SS. Treatment of late postoperative intraocular infections with intraocular injection of penicillin. Arch Ophthalmol 1947; 37: 304-307.
4. Rosengren B. 300 cases operated upon for retinal detachment; method and results. Acta Ophthalmol (Copenh) 1952; 30: 117-122.
5. Cibis PA, Becker B, Okun E, Canaan S. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol 1962; 68: 590-599.
6. Domínguez Collazo A, Fonseca Sandomingo A, Gómez Montaña J. Cirugía precoz y ambulatoria del desprendimiento de retina. Arch Soc Esp Oftalmol 1985; 48: 47-54.
7. Dominguez A. Pneumocasis. Madrid: Ed. IDIOSA; 1995.
8. Forster RK, Zachary IG, Cottingham AJ Jr, Norton EW. Further observations on the diagnosis, cause, and treatment of endophthalmitis. Am J Ophthalmol 1976; 81: 52-56.
9. Peyman GA, Vastine DW, Raichand M. Experimental aspects and their clinical application. Ophthalmology 1978; 85: 374-385.
10. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH Jr. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17-23.
11. Vitravene injection (fomivirsen sodium intravitreal injectable). Approval letter, pages 1-4. Vol 2004. US Food and Drug Administration. Disponible en: www.fda.gov/cder/foi/ nda/98/20961-Vitravene-Approv.pdf. Consultado el 29 de Abril de 2004.
12. Dominguez A, Quiroga P, Jareño M. El tratamiento de enfermedades médicas con triamcinolona intravítrea. Arch Soc Esp Oftalmol 1993; 65: 491-498.
13. Domínguez A. Dispositivos y medicamentos introducidos intraocularmente para el tratamiento en el consultorio de enfermedades de los ojos. An Real Acad Nac Med 1994; 61: 377-385.
14. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.
15. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247-248.
16. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108: 765-772.
17. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29: 2-6.
18. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for retinochoroidopathy. Arch Ophthalmol 2001; 119: 1380-1383.
19. Scott IU, Flynn HW Jr, Rosenfeld PJ. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 2003; 136: 737-739.
20. Gómez-Ulla F. Marticorena J, Alfaro DV 3rd, Fernández M, Méndez ER, Rothen M. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev 2006; 2: 99-112.
21. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-152.
22. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979-986.
23. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
24. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
25. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419- 1431.
26. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 335: 1432-1444.
27. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419- 1431.
28. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988-993.
29. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-998.
30. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
31. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 2006; 26: 1006-1013.
32. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
33. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24: 676-698.
34. Fung AE, Rosenfeld PJ, Reichel E. The International Bevacizumab safety Surrey: using the Internet to assess drug safety Worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
35. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87.
36. Moshfeghi AA. Rate of endophthalmitis after Anti-VGEF after intravitreal injection. Retina Today March/April 2008; 75-76.
37. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882.
38. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos M, Covarrubias P, Dominguez, F, Sanchez-Huerta V. Our Experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 2007; 22: 109-125.
39. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: 633-642.
40. Westfall AC, Osborn A, Kuhl D, Benz MS, Mieler WF, Holz ER. Acute endophthalmitis incidence. Intravitreal triamcinolone. Arch Ophthalmol 2005; 123: 1075-1077.
41. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796.
42. Jonisch J, Lai JC, Deramo VA, Flug AJ, Fastenberg DM. Increased incidence of sterile endophtahlmitis following itravitreal preserved triamcinolone. Br J Ophthalmol 2008; 92: 1051-1054.
43. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138: 489-492.
44. Moshfeghi DM, Kaiser PK, Bakri SJ, Kaiser RS, Maturi RK, Sears JE, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005; 36: 24-29.
45. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, Damico DJ, Flynn HW Jr, et al. Evolving guidelines for intravitreal injections. Retina 2004; 24: S3-S19.
46. Jaissle GB, Szurman P, Bartz-Schmidt KU. Empfehlung fur die Durcgfuhrung von intravitrealen Injektionen. Klin Monatsbl Augenheilkd 2005; 222: 390-395.
47. The Royal College of Ophthalmologists. Intravitrel injections Procedure Guideline. (www.rcophth.ac.uk/docs/z-old-website- documents/IVT-Inject- Guidelines-FINAL-for-website.pdf).
48. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98: 639-650.
49. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol 1997; 115: 357-361.
50. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996; 122: 1-17.
51. Leong JK, Shah R, McCluskey PJ, Benn RA, Taylor RF. Bacterial contamination of the anterior chamber during phacoemulsification cataract surgery. J Cataract Refract Surg 2002; 28: 826-833.
52. Hovding G, Sjursen H. Bacterial contamination of drops and dropper tips of in-use multidose eye drop bottles. Acta Ophthalmol (Copenh) 1982; 60: 213-222.
53. Kozak I, Cheng L, Freeman WR. Lidocaine gel anesthesia for intravitreal drug administration. Retina 2005; 25: 994- 998.
54. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Newton J, Miller D. Acute-onset endophthalmitis after cataract surger y (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005; 139: 983-987.
55. Ferguson AW, Scott JA, McGavigan J. Comparison of 5% povidone iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study .Br J Ophthalmol 2003; 87: 163-167.
56. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991; 98: 1769-1775.
57. Miño de Kaspar H, Chang RT, Singh K, Egbert PR, Blumenkranz MS, Ta CN. Prospective Randomized Comparison of 2 Different Methods of 5% Povidone-Iodine Applications for Anterior Segment Intraocular Surgery. Arch Ophthalmol 2005; 123: 161-165.
58. Isenberg S, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery IV: comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985; 103: 1340-1342.
59. Grimes S, Mein C, Trevino S. Preoperative antibiotic and povidone-iodine preparation of the eye. Ann Ophthalmol 1991; 23: 263-266.
60. Snyder-Perimutter L,Katz HR, Melia M. Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva. J Cataract Refract Surg 2000; 26: 1620-1625.
61. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 2002; 109: 2036-2041.
62. Osher RH, Amdahl LD, Cheetham JK. Antimicrobial efficacy and aqueous humor concentration of preoperative and postoperative topical trimethoprim/polymyxin B sulfate versus tobramycin. J Cataract Refract Surg 1994; 20: 3-8.
63. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006; 142: 721-725.
64. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006; 124: 479-483.
65. Bucci FA, Amico LM, Guerino A, Evans R. The effect of preop lid scrubs and levofloxacin on eyelid and conjunctival cultures prior to cataract surgery. Invest Ophthalmol Vis Sci 2003; 44: E-Abstract 1446-B342.